Martin-Perez D.,Lymphoma Group |
Sanchez E.,Hospital Nuestra Senora del Prado |
Maestre L.,Monoclonal Antibodies Unit |
Suela J.,Cytogenetics Unit |
And 6 more authors.
American Journal of Pathology | Year: 2010
Polycomb proteins are known to be of great importance in human cancer pathogenesis. SUZ12 is a component of the Polycomb PRC2 complex that, along with EZH2, is involved in embryonic stem cell differentiation. EZH2 plays an essential role in many cancer types, but an equivalent involvement of SUZ12 has not been as thoroughly demonstrated. Here we show that SUZ12 is anomalously expressed in human primary tumors, especially in mantle cell lymphoma (MCL), pulmonary carcinomas and melanoma, and is associated with gene locus amplification in some cases. Using MCL as a model, functional and genomic studies demonstrate that SUZ12 loss compromises cell viability, increases apoptosis, and targets genes involved in central oncogenic pathways associated with MCL pathogenesis. Our results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of MCL, such as abnormal DNA repair and increased resistance to apoptosis. Copyright © American Society for Investigative Pathology.
Cugat E.,Hepato Bilio Pancreatic Unit |
Perez-Romero N.,Hepato Bilio Pancreatic Unit |
Rotellar F.,Hepato Bilio Pancreatic Unit |
Suarez M.A.,Hepato Bilio Pancreatic Unit |
And 11 more authors.
Journal of Hepato-Biliary-Pancreatic Sciences | Year: 2010
Background: To present the data of laparoscopy in liver surgery and to assess the real indications and outcomes of this kind of approach. Methods: From February 2000 to March 2008, a prospective study was performed on 182 patients from 15 Spanish surgical centres. Results: A total of 308 lesions was collected. The mean age was 57 years old, and 61.5% were female. Among patients with cystic lesions we found: 45 simple cysts, 19 policystic diseases, 12 hydatidic cysts and 2 cystoadenomas. Among solid lesions (n = 104), we found 34 patients with benign pathology (12 focal nodular hyperplasia, 10 adenomas, 7 haemangyomas and 5 other lesions) and 70 with malignant pathology (38 metastases, 29 hepatocellular carcinomas, 2 cholangiocarcinomas and 1 lymphoma). The global rate of conversion was 8.8%. The global morbidity rate was 14.8%, and 5 of them required re-intervention. Conclusions: Nowadays there are strong criteria for patients being submitted to laparoscopy procedures based both on type and location features. The postoperative morbidity rate is low, also for hepatocellular carcinoma in cirrhotic liver. In case of malignant pathology, we think the use of ultrasonography is mandatory to obtain a free margin, which implies a long-term survival rate. © Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2009.
Panizo C.,Hospital Nuestra Senora del Prado |
Cimarra M.,Hospital Clinico San Carlos |
Gonzalez-Mancebo E.,Hospital Fuenlabrada |
Vega A.,Hospital Universitario Of Guadalajara |
And 2 more authors.
Journal of Investigational Allergology and Clinical Immunology | Year: 2010
Background: The fast-dissolving grass allergy immunotherapy tablet (grass AIT), Grazax, has proven effective in grass pollen-induced rhinoconjunctivitis. Objective: To investigate the immunological and cutaneous changes induced after a short course with grass AIT. Methods: We performed a randomized, double-blind placebo-controlled trial with 78 patients randomly assigned to receive either grass AIT or placebo in a 2:1 ratio. Treatment lasted at least 8 weeks before the grass pollen season (GPS), and continued until the season finished. Specific immunoglobulin (Ig) G4, IgE, and IgE-blocking factor to Phleum pratense were measured at the beginning of the trial and at different intervals during treatment. Immediate and delayed skin tests with P pratense were also performed. Safety endpoints were defi ned in terms of adverse events reported. Results: A total of 75 patients completed the trial (50 active and 25 placebo). P pratense IgG4, IgE, and IgE-blocking factor in actively treated patients increased significantly from baseline to the start of the GPS compared to placebo (P>.001, P=.017, and P=.005, respectively) The immediate cutaneous response was reduced during therapy in actively treated subjects, whereas placebo-treated subjects showed a decrease only after the start of the GPS. The delayed response to the intradermal test in grass AIT-treated subjects diminished, although not in a significantly different way from the placebo-treated subjects. Conclusion: Treatment with grass AIT for grass pollen allergic rhinoconjunctivitis induces immunological changes after only 1 month of treatment. © 2010 Esmon Publicidad.
Meca-Lallana J.E.,Hospital Universitario Virgen Of La Arrixaca |
Balseiro J.J.,Hospital Universitario Of Getafe |
Lacruz F.,Hospital Universitario Of Navarra |
Guijarro C.,Hospital Universitario 12 Of Octubre |
And 5 more authors.
Journal of the Neurological Sciences | Year: 2012
Background: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-β (IFN-β). Objective: To evaluate changes in spasticity in MS patients switching from IFN-β to GA. Methods: Observational, multicentre study in patients with relapsing-remitting MS (RRMS) and spasticity switching from IFN-β to GA. The primary endpoint comprised changes on Penn Spasm Frequency Scale (PSFS), Modified Ashworth Scale (MAS), Adductor Tone Rating Scale (ATRS), and Global Pain Score (GPS) at months 3 and 6 after starting GA. Results: Sixty-eight evaluable patients were included (mean age,41.7 ± 9.5 years; female,70.6%; mean time from MS diagnosis to starting GA,7.6 ± 5.7 years). Previous treatments were subcutaneous IFN-β1a in 42.6% patients, intramuscular IFN-β1a in 41.2% and IFN-β1b in 32.4%, whose mean durations were 3.5 ± 3.3, 2.7 ± 2.5 and 4.4 ± 3.6 years, respectively. Statistically significant reductions in mean scores on all spasticity measurements were observed from baseline to month 3 (PSFS, 1.7 ± 0.9 vs 1.4 ± 0.6, p < 0.01; MAS, 0.7 ± 0.5 vs 0.6 ± 0.5, p < 0.01; highest MAS score, 1.9 ± 0.8 vs 1.7 ± 0.8, p < 0.01; ATRS, 1.6 ± 0.6 vs 1.4 ± 0.6, p < 0.01; GPS, 29.4 ± 22.1 vs 24.7 ± 19.4, p < 0.01) and from baseline to month 6 (PSFS, 1.7 ± 0.9 vs 1.3 ± 0.6, p < 0.01; MAS, 0.7 ± 0.5 vs 0.5 ± 0.5, p < 0.01; highest MAS score, 1.9 ± 0.8 vs 1.5 ± 0.9, p < 0.01; ATRS, 1.6 ± 0.6 vs 1.3 ± 0.6, p < 0.01; GPS, 29.4 ± 22.1 vs 19.1 ± 14.8, p < 0.01). Conclusion: Spasticity improvement in terms of spasm frequency, muscle tone and pain can be noted after three months and prolonged for six months of GA treatment. © 2011 Elsevier B.V. All rights reserved.
De La Piedra C.,Institute Investigacion Sanitaria Fundacion Jimenez Daz |
Quiroga I.,Hospital Nuestra Senora del Prado |
Montero M.,Institute Investigacion Sanitaria Fundacion Jimenez Daz |
Dapia S.,Trabeculae Technology Based Firm |
And 4 more authors.
Aging Male | Year: 2011
Aim. The aim of this study was to investigate the effects of the bisphosphonate ibandronate (IBN) in a male osteoporosis animal model. Methods. Two studies were performed in 9-month-old orchidectomised (ORX) or sham-operated rats. In prevention study, subcutaneous IBN was administered daily (1μg/kg) or monthly (28μg/kg every 28 days) starting on day of surgery for 5 months. In treatment study, the same treatment started 6 months after ORX. After sacrifice, bone analyses by dual-energy X-ray absorptiometry, 3-dimensional micro-computed tomography, and 3-point bending were performed in femora or vertebrae. Serum tartrate-resistant acid phosphatase 5b (TRAP-5b) and aminoterminal propeptide of collagen I (PINP) were analysed for resorption and osteocalcin (BGP) for bone formation. Results.In both studies, ORX resulted in significant femoral and vertebral bone loss and microarchitectural deterioration after 5 months of ORX, and became more pronounced after 11 months. Biomechanical strength was also decreased. Serum levels for TRAP-5b and BGP increased while PINP levels were reduced or unchanged. Both daily and monthly IBN prevented or even restored ORX-induced changes in both studies, with the intermittent regimen showing a improvement in efficacy with respect to many of the biomechanical parameters. © 2011 Informa UK, Ltd.